226 related articles for article (PubMed ID: 19200274)
21. Intravenous Iron Use in the Care of Patients with Kidney Disease.
Macdougall IC
Clin J Am Soc Nephrol; 2019 Oct; 14(10):1528-1530. PubMed ID: 31175103
[No Abstract] [Full Text] [Related]
22. Iron status and benefit of the use of parenteral iron therapy in pre-dialysis Chronic Kidney disease patients.
Arogundade FA; Soyinka FO; Sanusi AA; Ojo OE; Akinsola A
Niger Postgrad Med J; 2013 Dec; 20(4):299-304. PubMed ID: 24633272
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of oral and intravenous iron therapy in haemodialysis patients.
Jenq CC; Tian YC; Wu HH; Hsu PY; Huang JY; Chen YC; Fang JT; Yang CW
Int J Clin Pract; 2008 Mar; 62(3):416-22. PubMed ID: 17511797
[TBL] [Abstract][Full Text] [Related]
24. Iron replacement and supplementation in patients with chronic kidney disease.
Wazny LD; Raymond CB
CANNT J; 2011; 21(4):26-30; quiz 31-2. PubMed ID: 22324122
[TBL] [Abstract][Full Text] [Related]
25. Update on intravenous iron choices.
Larson DS; Coyne DW
Curr Opin Nephrol Hypertens; 2014 Mar; 23(2):186-91. PubMed ID: 24401789
[TBL] [Abstract][Full Text] [Related]
26. [Intravenous ferric carboxymaltose for the treatment of anemia in chronic renal disease].
Merino JL; Bueno B; Campos MA; Amézquita Y
Rev Clin Esp (Barc); 2014; 214(5):282-3. PubMed ID: 24582410
[No Abstract] [Full Text] [Related]
27. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran?
Sav T; Tokgoz B; Sipahioglu MH; Deveci M; Sari I; Oymak O; Utas C
Ren Fail; 2007; 29(4):423-6. PubMed ID: 17497463
[TBL] [Abstract][Full Text] [Related]
28. Creative iron management--a practical guide.
Jenkins K
J Ren Care; 2009 Dec; 35 Suppl 2():32-5. PubMed ID: 19891684
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy and tolerability of ferric carboxymaltose in geriatric patients with anemia. Data from three non-interventional studies].
Röhrig G; Steinmetz T; Stein J; Geisel T; Virgin G; Schaefer R; Bach M; Schulz RJ
MMW Fortschr Med; 2014 Jul; 156 Suppl 2():48-53. PubMed ID: 25351027
[TBL] [Abstract][Full Text] [Related]
30. Stabilizing hemoglobin levels: what's new in IV iron and anemia management?
Fishbane S; Larson K; VanBuskirk S
Nephrol Nurs J; 2008; 35(5):493-502. PubMed ID: 18856080
[TBL] [Abstract][Full Text] [Related]
31. Ferric carboxymaltose: a review of its use in iron deficiency.
Keating GM
Drugs; 2015 Jan; 75(1):101-27. PubMed ID: 25428711
[TBL] [Abstract][Full Text] [Related]
32. Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
Tagboto S; Cropper L; Mostafa S; Turner J; Bailey G; Pugh-Clarke K
J Ren Care; 2008 Sep; 34(3):112-5. PubMed ID: 18786076
[TBL] [Abstract][Full Text] [Related]
33. Lost without directions: lessons from the anemia debate and the drive study.
Spiegel DM; Chertow GM
Clin J Am Soc Nephrol; 2009 May; 4(5):1009-10. PubMed ID: 19357246
[TBL] [Abstract][Full Text] [Related]
34. Clinical perspective: iron replacement therapy in chronic heart failure.
Cowie MR; Lucas R
Int J Clin Pract; 2011 Jun; 65(6):645-8. PubMed ID: 21564435
[No Abstract] [Full Text] [Related]
35. Iron deficiency and anaemia in bariatric surgical patients: causes, diagnosis and proper management.
Muñoz M; Botella-Romero F; Gómez-Ramírez S; Campos A; García-Erce JA
Nutr Hosp; 2009; 24(6):640-54. PubMed ID: 20049366
[TBL] [Abstract][Full Text] [Related]
36. Effects of intravenous iron on mononuclear cells during the haemodialysis session.
Martin-Malo A; Merino A; Carracedo J; Alvarez-Lara MA; Ojeda R; Soriano S; Crespo R; Ramirez R; Aljama P
Nephrol Dial Transplant; 2012 Jun; 27(6):2465-71. PubMed ID: 22207322
[TBL] [Abstract][Full Text] [Related]
37. Improving efficiency and value in health care. Intravenous iron management for anaemia associated with chronic kidney disease: linking treatment to an outpatient clinic, optimizing service provision and patient choice.
Bhandari S; Naudeer S
J Eval Clin Pract; 2008 Dec; 14(6):996-1001. PubMed ID: 18785894
[TBL] [Abstract][Full Text] [Related]
38. Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections.
Macdougall IC; Roche A
Am J Kidney Dis; 2005 Aug; 46(2):283-9. PubMed ID: 16112047
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and toxicity of intravenous iron in a mouse model of critical care anemia*.
Heming N; Lettéron P; Driss F; Millot S; El Benna J; Tourret J; Denamur E; Montravers P; Beaumont C; Lasocki S
Crit Care Med; 2012 Jul; 40(7):2141-8. PubMed ID: 22564959
[TBL] [Abstract][Full Text] [Related]
40. An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic.
Wilson PD; Hutchings A; Jeans A; Macdougall IC
J Med Econ; 2013; 16(1):108-14. PubMed ID: 22989163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
